Dr. Breitfeld is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2115 Meadowcreek Dr
Durham, NC 27705- Is this information wrong?
Education & Training
- Children's Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1982 - 1985
- University of RochesterResidency, Pediatrics, 1979 - 1982
- University of Rochester School of Medicine and DentistryClass of 1979
- Princeton UniversityAB, Chemistry, 1971 - 1975
Certifications & Licensure
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma Start of enrollment: 2001 Nov 01
Publications & Presentations
PubMed
- 20 citationsRisk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology GroupLeo Mascarenhas, Elizabeth R. Lyden, Philip P. Breitfeld, David O. Walterhouse, Sarah S. Donaldson, David A. Rodeberg, David M. Parham, James R. Anderson, William H. M...> ;Cancer. 2019 Aug 1
- 65 citationsFactors associated with failure of oncology drugs in late-stage clinical development: A systematic reviewDenis Leonardo Fontes Jardim, Eric S. Groves, Philip P. Breitfeld, Razelle Kurzrock> ;Cancer Treatment Reviews. 2017 Jan 1
- 73 citationsRandomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the C...Leo Mascarenhas, Elizabeth Lyden, Philip P. Breitfeld, David O. Walterhouse, Sarah S. Donaldson, Charles N. Paidas, David M. Parham, James R. Anderson, William H. Meye...> ;Journal of Clinical Oncology. 2010 Oct 20
- Join now to see all
Press Mentions
- Fannin/Allterum Awarded $2 Million SBIR Phase II Grant from NIH to Advance Monoclonal Antibody for Treating Childhood LeukemiaMay 8th, 2023
- Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior LeadershipNovember 29th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: